U.S. markets close in 6 minutes
  • S&P 500

    4,431.63
    -42.12 (-0.94%)
     
  • Dow 30

    34,568.17
    -183.15 (-0.53%)
     
  • Nasdaq

    15,035.33
    -146.60 (-0.97%)
     
  • Russell 2000

    2,228.01
    -4.90 (-0.22%)
     
  • Crude Oil

    72.02
    -0.59 (-0.81%)
     
  • Gold

    1,752.20
    -4.50 (-0.26%)
     
  • Silver

    22.41
    -0.39 (-1.71%)
     
  • EUR/USD

    1.1734
    -0.0037 (-0.32%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3743
    -0.0054 (-0.39%)
     
  • USD/JPY

    109.9500
    +0.2320 (+0.21%)
     
  • BTC-USD

    47,376.12
    -346.90 (-0.73%)
     
  • CMC Crypto 200

    1,200.42
    -25.11 (-2.05%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Viemed Healthcare Stock Appears To Be Modestly Undervalued

·4 min read

- By GF Value

The stock of Viemed Healthcare (NAS:VMD, 30-year Financials) shows every sign of being modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $8.47 per share and the market cap of $336.7 million, Viemed Healthcare stock is believed to be modestly undervalued. GF Value for Viemed Healthcare is shown in the chart below.


Viemed Healthcare Stock Appears To Be Modestly Undervalued
Viemed Healthcare Stock Appears To Be Modestly Undervalued

Because Viemed Healthcare is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth, which averaged 38% over the past three years and is estimated to grow 14.84% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Viemed Healthcare has a cash-to-debt ratio of 3.23, which ranks in the middle range of the companies in the industry of Medical Devices & Instruments. Based on this, GuruFocus ranks Viemed Healthcare's financial strength as 8 out of 10, suggesting strong balance sheet. This is the debt and cash of Viemed Healthcare over the past years:

Viemed Healthcare Stock Appears To Be Modestly Undervalued
Viemed Healthcare Stock Appears To Be Modestly Undervalued

Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. Viemed Healthcare has been profitable 5 years over the past 10 years. During the past 12 months, the company had revenues of $135.9 million and earnings of $0.71 a share. Its operating margin of 13.97% better than 72% of the companies in the industry of Medical Devices & Instruments. Overall, GuruFocus ranks Viemed Healthcare's profitability as fair. This is the revenue and net income of Viemed Healthcare over the past years:

Viemed Healthcare Stock Appears To Be Modestly Undervalued
Viemed Healthcare Stock Appears To Be Modestly Undervalued

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Viemed Healthcare is 38%, which ranks better than 90% of the companies in the industry of Medical Devices & Instruments. The 3-year average EBITDA growth rate is 46%, which ranks better than 82% of the companies in the industry of Medical Devices & Instruments.

One can also evaluate a company's profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely creating value for its shareholders. During the past 12 months, Viemed Healthcare's ROIC is 30.51 while its WACC came in at 6.47. The historical ROIC vs WACC comparison of Viemed Healthcare is shown below:

Viemed Healthcare Stock Appears To Be Modestly Undervalued
Viemed Healthcare Stock Appears To Be Modestly Undervalued

To conclude, the stock of Viemed Healthcare (NAS:VMD, 30-year Financials) shows every sign of being modestly undervalued. The company's financial condition is strong and its profitability is fair. Its growth ranks better than 82% of the companies in the industry of Medical Devices & Instruments. To learn more about Viemed Healthcare stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.